English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/74837
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Dobesilate is an angiogenesis inhibitor

AuthorsCuevas, Pedro; Sánchez, Isabel; Lozano, R.M. ; Giménez-Gallego, Guillermo
Issue Date2005
PublisherBioMed Central
CitationEuropean Journal of Medical Research, 10 (9) : 369- 372 (2005)
AbstractAberrant angiogenesis is essential for the progression of solid tumors and hematological malignancies. Antiangiogenic therapy is one of the most promising approaches to treat such diseases. Dobesilate is an oral agent for treatment of vascular complications of diabetic retinopathy. We have examined the possibility that this compound could interfere with the process of angiogenesis in a mouse gelatine sponge assay using acidic fibroblast growth factor (aFGF) as an inducer of neovascularization. According to the results reported here, dobesilate remarkably reduced vessel ingrowth in aFGF-containing subcutaneous sponges in mice. These findings suggest that dobesilate could be an effective agent in the treatment of angiogenesis-dependent diseases involving FGFs. © I. Holzapfel Publishers 2005.
Identifiersissn: 0949-2321
e-issn: 2047-783X
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Eur. J.Med. Res. 10 (369-372).pdf735,23 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.